Patrice Merrin - Novadaq Technologies Director
| NVDQ Etf | 5.01 0.25 5.25% |
Ms. Patrice E. Merrin is Independent Director of the Company. She is a corporate director and is currently a nonexecutive director of Glencore PLC and Stillwater Mining Company. Ms. Merrin was Chairman of the Board of CML HealthCare Inc., a leading provider of medical laboratory testing services, from 2011 to 2013, having served as a director since 2008. She was a director of Ornge, the Province of Ontario air ambulance and medical transport service, from 2012 to 2015. Ms. Merrin served as President, CEO and Director of Luscar Ltd., then owned equally by Sherritt International Corporation and Ontario Teachers Pension Plan Board, from 2005 to 2006, prior to which she served as Executive VicePresident and Chief Operating Officer of Sherritt International from 1999 to 2004. She cochairs the Leadership Council of Perimeter Institute for Theoretical Physics as well as its Emmy Noether Circle which aims to support and fund women in physics and mathematical physics at Perimeter
| Age | 67 |
| Tenure | 9 years |
| Address | 5090 Explorer Drive, Suite 202 L4W 4TW,Mississauga,CAN |
| Phone | 905-629-3822 |
| Web | www.novadaq.com |
| Issuer | Tuttle Capital Management |
| Inception Date | 2023-10-19 |
| Entity Type | Regulated Investment Company |
| Asset Under Management | 12.95 Million |
| Asset Type | Equity |
| Category | Strategy |
| Focus | Single Stock |
| Market Concentration | Developed Markets |
| Region | North America |
| Administrator | Commonwealth Fund Services, Inc. |
Similar Fund Executives
| Showing other executives | One Year Return | ||
| Rick Lund | Veeva Systems Class | N/A | |
| Timothy | Cigna Corp | N/A | |
| Jeffrey Davis | Laboratory of | 57 | |
| Richelle Parham | Laboratory of | 53 | |
| John Cardis | Edwards Lifesciences Corp | 73 | |
| Eric Foss | Cigna Corp | 62 | |
| Manuel Kadre | Mednax Inc | 54 | |
| Paul Sekhri | Veeva Systems Class | 62 | |
| Robert Mittelstaedt | Laboratory of | 74 | |
| Bahija Jallal | Guardant Health | 56 | |
| Robert Williams | Laboratory of | 72 | |
| Steven Loranger | Edwards Lifesciences Corp | 69 | |
| Aaref Hilaly | Guardant Health | 46 | |
| William Zollars | Cigna Corp | 70 | |
| Michelle Gass | Cigna Corp | 47 | |
| Ronald Codd | Veeva Systems Class | 64 | |
| Paul Chamberlain | Veeva Systems Class | 56 | |
| John Partridge | Cigna Corp | 71 | |
| Gunnar Hansen | Veeva Systems Class | N/A | |
| James Rogers | Cigna Corp | 69 | |
| Ramona Sequeira | Edwards Lifesciences Corp | 55 | |
Novadaq Technologies Money Managers
| Anthony Griffiths, Independent Non-Executive Chairman of the Board | ||
| Patrice Merrin, Director | ||
| Lori Swalm, VP of Marketing | ||
| Thomas Wellner, Independent Director | ||
| Lisa Colleran, Director | ||
| Arun Menawat, President CEO, Director | ||
| Rick Mangat, Co-Founder, Sr. VP and General Manager | ||
| Harold Koch, Independent Director | ||
| David Martin, IR Contact Officer | ||
| Robert White, Director | ||
| Karen Licitra, Director | ||
| Aaron Davidson, Independent Director | ||
| Derrick Guo, General Counsel | ||
| William MacKinnon, Independent Director | ||
| Roger Deck, Vice President - Operations |
Novadaq Etf Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right etf is not an easy task. Is Novadaq Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Price To Earning | (12.09) X | ||||
| Revenue | 80.07 M | ||||
| EBITDA | (50.47 M) | ||||
| Net Income | (52.91 M) | ||||
| Cash And Equivalents | 49.59 M | ||||
| Cash Per Share | 0.86 X | ||||
| Total Debt | 250 K | ||||
| Debt To Equity | 10.70 % | ||||
| Current Ratio | 3.49 X | ||||
| Book Value Per Share | 1.54 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novadaq Technologies in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novadaq Technologies' short interest history, or implied volatility extrapolated from Novadaq Technologies options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novadaq Technologies. Also, note that the market value of any etf could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Novadaq Etf, please use our How to Invest in Novadaq Technologies guide.Note that the Novadaq Technologies information on this page should be used as a complementary analysis to other Novadaq Technologies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
The market value of Novadaq Technologies is measured differently than its book value, which is the value of Novadaq that is recorded on the company's balance sheet. Investors also form their own opinion of Novadaq Technologies' value that differs from its market value or its book value, called intrinsic value, which is Novadaq Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novadaq Technologies' market value can be influenced by many factors that don't directly affect Novadaq Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novadaq Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novadaq Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novadaq Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.